What is Claimed:

10

20

1. A compound having the structure:

$$R_2$$
 R_3
 R_3
 R_4
 R_1
 R_1
 R_1

wherein $\underline{----}$ is CH_2 , O, -CO-, $-CO_2$ -, $-CH_2$ - CH_2 - or -CHCH-;

wherein t is 0 or 1, and where the cyclic ring containing t is 5 or 6-membered;

wherein n is an integer from 1 to 6 inclusive;

wherein each R_1 and R_2 is independently -H, -F, -Cl, -Br, -I; straight chained or branched C_1 - C_7 alkyl, monofluoroalkyl or polyfluoroalkyl, aryl or heteroaryl;

wherein each R_3 is independently -H; C_1 - C_6 straight chained or branched alkyl; aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -I, -R₂, straight chained or branched C_1 - C_7 alkyl, aryl, phenoxy or heteroaryl; and

where two R_3 moieties taken together can form a C_3 - C_6 cycloalkyl;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 having the structure:

$$R_2$$
 R_3
 R_3
 R_4
 R_1
 R_1

5 wherein n, R_1 , R_2 and R_3 are as defined in claim 1.


3. The compound of claim 2 having the structure:

$$R_2$$
 R_3
 R_1
 R_1
 R_1

wherein R_3 is C_1 - C_6 straight chained or branched alkyl or aryl, wherein the aryl is optionally substituted with one or more -F, -Cl, -Br, -I, - R_2 , straight chained or branched C_1 - C_7 alkyl, aryl, phenoxy or heteroaryl; and

wherein n, R_1 and R_2 are as defined in claim 1.

4. The compound of claim 3 having the structure:



wherein n, R_1 and R_2 are as defined in claim 1.

5. The compound of claim 4 having the structure:

wherein each R_1 and R_2 is independently -H, -F, -Cl, -Br, -I; straight chained or branched C_1 - C_7 alkyl, aryl or heteroaryl; and

wherein n is as defined in claim 1.

6. The compound of claim 5 having the structure:

$$R_2$$

10

5

wherein R_1 and R_2 are as defined in claim 1.

7. The compound of claim 6 having the structure:

wherein each R_2 is as defined in claim 1.

8. The compound of claim 7 having the structure:

9. The compound of claim 7 having the structure:

The compound of claim 7 having the structure: 10.

The compound of claim 2 having the structure: 11.

$$R_2$$
 R_3
 R_3
 R_4
 R_1
 R_1


5

wherein each R_3 is independently H or $C_1\text{-}C_6$ straight chained or branched alkyl; and

wherein n, $R_{\rm 1}$ and $R_{\rm 2}$ are as defined in claim 1.

10

The compound of claim 11 having the structure: 12.



wherein each R_3 is $C_1\text{-}C_6$ straight chained or branched alkyl; and

15

wherein R_1 and R_2 are as defined in claim 1.

13.

The compound of claim 12 having the structure:

wherein each R₁ is F, Cl, Br or C₁-C₃ alkyl;

wherein each R_3 is independently H or C_1 - C_7 straight chained or branched alkyl; and

wherein R_2 is as defined in claim 1.

10 14. The compound of claim 13 having the structure:

15. The compound of claim 2 having the structure:

wherein the two R_3 moieties taken together form a C_3 - C_6 cycloalkyl; and

wherein n, R_1 and R_2 are as defined in claim 1.

16. The compound of claim 15 having the structure:

$$R_2$$
 R_3
 R_3
 R_4
 R_1
 R_1

20 wherein the two R. mojeties taken

wherein the two R_3 moieties taken together form a C_4 - C_6 cycloalkyl;

wherein each R_1 and R_2 is independently -H, -F, -Cl, -Br, -I; or straight chained or branched C_1 - C_7 alkyl; and

- 5 wherein n is as defined in claim 1.
 - 17. The compound of claim 16 having the structure:

- wherein R_2 is -H, -F, -Cl, -Br, -I.
 - 18. The compound of claim 17 having the structure:

19. The compound of claim 1 having the structure:

15

wherein n, R_1 , R_2 and R_3 are as defined in claim 1.

20. The compound of claim 19 having the structure:

wherein R_3 is C_1 - C_6 straight chained or branched alkyl or aryl wherein the aryl is optionally substituted

with one or more -F, -Cl, -Br, -I, -R₂, straight chained or branched C_1 - C_7 alkyl, aryl, phenoxy or heteroaryl; and

- wherein n, R_1 and R_2 are as defined in claim 1.
 - 21. The compound of claim 20 having the structure:

wherein n, R_1 and R_2 are as defined in claim 1.

22. The compound of claim 21 having the structure:

10

wherein n, $R_{\rm 1}$ and $R_{\rm 2}$ are as defined in claim 1.

15 23. The compound of claim 22 having the structure:

wherein each R_1 and R_2 is independently -H, -F, -Cl, -Br, -I; straight chained or branched C_1 - C_7 alkyl.

20 24. The compound of claim 23 having the structure:

wherein each R_{1} is independently -F, -Cl, -Br, -I; or straight chained or branched $C_{1}\text{-}C_{7}$ alkyl.

25. The compound of claim 24 having the structure:

26. The compound of claim 23 having the structure:

5

10

15

wherein R_1 is F, Cl, Br, I or $C_1\text{-}C_7$ straight chained or branched alkyl.

27. The compound of claim 26 having the structure:

28. The compound of claim 26 having the structure:

29. A compound having the structure:

$$R_2$$
 R_2
 R_2
 R_2

wherein each R_2 is independently H, F, Cl, Br, CN or $C_1\text{-}C_7$ straight chained or branched alkyl;

5

wherein X is CH2 or O; and

wherein n is an integer from 1 to 6 inclusive.

10 30. The compound of claim 29 having the structure:

wherein each R_{2} is independently H, F, Cl or Br; and wherein n is an integer from 1 to 6 inclusive.

31. The compound of claim 30 having the structure:

20

15

wherein each R2 is independently H, F, Cl or Br; and wherein n is an integer from 3 to 6 inclusive.

32. The compound of claim 31 having the structure:

$$R_2$$
 R_2
 R_2

- 5 wherein each R₂ is F, Cl or Br.
 - 33. The compound of claim 31 having the structure:

- 34. A pharmaceutical composition which comprises a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
- 35. A pharmaceutical composition made by admixing a compound of claim 1 and a pharmaceutically acceptable carrier.
 - 36. A process for making a pharmaceutical composition comprising admixing a compound of claim 1 and a pharmaceutically acceptable carrier.
- 37. A method of treating a subject suffering from a disorder mediated by the MCH1 receptor comprising administering to the subject a therapeutically effective amount of a compound of claim 1.

- 38. The method of claim 37, wherein the therapeutically effective amount is between about 0.03 and about 300 mg.
- 5 39. The method of claim 37, wherein the disorder is depression.

10

- 40. The method of claim 37, wherein the disorder is anxiety.
- 41. The method of claim 37, wherein the disorder is obesity.
- 42. The method of claim 37, wherein the disorder is urge incontinence.
- 43. A method of treating a subject suffering from depression, anxiety, urge incontinence or obesity comprising administering to the subject a therapeutically effective amount of a compound of claim 1.
- 44. The method of claim 43 wherein the therapeutically effective amount is an amount between about 0.03 and about 300 mg.
 - 45. The method of claim 43, wherein the subject suffers from depression.
- 30 46. The method of claim 43, wherein the subject suffers from anxiety.
 - 47. The method of claim 43, wherein the subject suffers from obesity.
 - 48. The method of claim 43, wherein the subject suffers from urge incontinence.

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.